DOMH vs. MNPR, TRIB, KPRX, AIH, RDHL, AVTX, PIRS, COEP, MBOT, and NXGL
Should you be buying Dominari stock or one of its competitors? The main competitors of Dominari include Monopar Therapeutics (MNPR), Trinity Biotech (TRIB), Kiora Pharmaceuticals (KPRX), Aesthetic Medical International Holdings Group (AIH), RedHill Biopharma (RDHL), Avalo Therapeutics (AVTX), Pieris Pharmaceuticals (PIRS), Coeptis Therapeutics (COEP), Microbot Medical (MBOT), and NEXGEL (NXGL). These companies are all part of the "medical" sector.
Monopar Therapeutics (NASDAQ:MNPR) and Dominari (NASDAQ:DOMH) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment, risk, community ranking and earnings.
In the previous week, Monopar Therapeutics had 6 more articles in the media than Dominari. MarketBeat recorded 11 mentions for Monopar Therapeutics and 5 mentions for Dominari. Dominari's average media sentiment score of 0.57 beat Monopar Therapeutics' score of 0.25 indicating that Monopar Therapeutics is being referred to more favorably in the media.
Monopar Therapeutics presently has a consensus target price of $2.00, indicating a potential upside of 192.65%. Given Dominari's higher possible upside, equities research analysts clearly believe Monopar Therapeutics is more favorable than Dominari.
Monopar Therapeutics has a beta of 1.17, indicating that its share price is 17% more volatile than the S&P 500. Comparatively, Dominari has a beta of 0.92, indicating that its share price is 8% less volatile than the S&P 500.
1.8% of Monopar Therapeutics shares are held by institutional investors. Comparatively, 42.5% of Dominari shares are held by institutional investors. 41.6% of Monopar Therapeutics shares are held by insiders. Comparatively, 9.7% of Dominari shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Monopar Therapeutics received 39 more outperform votes than Dominari when rated by MarketBeat users.
Monopar Therapeutics has higher earnings, but lower revenue than Dominari. Monopar Therapeutics is trading at a lower price-to-earnings ratio than Dominari, indicating that it is currently the more affordable of the two stocks.
Monopar Therapeutics has a net margin of 0.00% compared to Monopar Therapeutics' net margin of -721.11%. Monopar Therapeutics' return on equity of -38.40% beat Dominari's return on equity.
Summary
Monopar Therapeutics beats Dominari on 10 of the 15 factors compared between the two stocks.
Get Dominari News Delivered to You Automatically
Sign up to receive the latest news and ratings for DOMH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DOMH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Dominari Competitors List
Related Companies and Tools
